Skip to menu Skip to content Skip to footer

2002

Conference Publication

Long-term outcome following high-dose therapy with etoposide, melphalan, TBI and autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML).

Mollee, P, Gupta, V, Song, K, Tsang, R, Crump, M and Keating, A (2002). Long-term outcome following high-dose therapy with etoposide, melphalan, TBI and autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML).. 44th Annual Meeting of the American-Society-of-Hematology, Philadelphia Pennsylvania, Dec 06-10, 2002.

Long-term outcome following high-dose therapy with etoposide, melphalan, TBI and autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML).

2002

Conference Publication

Allogeneic stem cell transplantation for idiopathic myelofibrosis in Australasia

Durrant, S, Szer, J, Bradstock, K, Nivison-Smith, I and Mollee, P (2002). Allogeneic stem cell transplantation for idiopathic myelofibrosis in Australasia. 23rd Annual Scientific Meeting of the Transplantation-Society-of-Australia-and-New-Zealand, Canberra Australia, May 11-13, 2005. LONDON: NATURE PUBLISHING GROUP.

Allogeneic stem cell transplantation for idiopathic myelofibrosis in Australasia

2001

Conference Publication

Prolonged engraftment and transgene expression of genetically modified autologous bone marrow stromal (mesenchymal) cells after infusion post autotransplant: A platform for cell and gene therapy.

Keating, A, Filshie, R, Mollee, P and Wang, XH (2001). Prolonged engraftment and transgene expression of genetically modified autologous bone marrow stromal (mesenchymal) cells after infusion post autotransplant: A platform for cell and gene therapy.. WASHINGTON: AMER SOC HEMATOLOGY.

Prolonged engraftment and transgene expression of genetically modified autologous bone marrow stromal (mesenchymal) cells after infusion post autotransplant: A platform for cell and gene therapy.

2001

Conference Publication

Low dose valaciclovir for the prevention of CMV disease post allogeneic bone marrow transplantation

Irving, I, Williamson, J, Mollee, P, Morton, AJ, Sloots, T, Siebert, D and Durrant, S (2001). Low dose valaciclovir for the prevention of CMV disease post allogeneic bone marrow transplantation. BASINGSTOKE: NATURE PUBLISHING GROUP.

Low dose valaciclovir for the prevention of CMV disease post allogeneic bone marrow transplantation

2001

Conference Publication

Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.

Durrant, S., Irving, I., Mollee, P., Morton, A. J., Webb, M. and Macfarlane, D. (2001). Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.. 27th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, United Kingdom: Nature Publishing Group.

Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.

2000

Conference Publication

Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GVHD.

Mollee, P, Morton, J, Irving, I and Durrant, S (2000). Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GVHD..

Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GVHD.

2000

Conference Publication

A Phase II study of Interferon alpha and intermittent oral Cytarabine in the treatment of newly diagnosed Chronic Myeloid Leukaemia.

Mollee, P., Taylor, K., Arthur, C., Wright, S., Rodwell, R. and Taylor, D. (2000). A Phase II study of Interferon alpha and intermittent oral Cytarabine in the treatment of newly diagnosed Chronic Myeloid Leukaemia.. Perth, July 2000. Sydney: Haematology Society of Australia and New Zealand.

A Phase II study of Interferon alpha and intermittent oral Cytarabine in the treatment of newly diagnosed Chronic Myeloid Leukaemia.

2000

Conference Publication

A phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML)

Mollee, P., Taylor, K., Arthur, C., Wright, S. and Morton, J. (2000). A phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML). 2nd Annual Scientific Meeting of the Haematology Society of Australia and New Zealand, Perth, WA, 25-28 July 2000. Washington, D.C.: American Society of Hematology.

A phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML)